WO2007100151A1 - Agent immunostimulant - Google Patents

Agent immunostimulant Download PDF

Info

Publication number
WO2007100151A1
WO2007100151A1 PCT/JP2007/054597 JP2007054597W WO2007100151A1 WO 2007100151 A1 WO2007100151 A1 WO 2007100151A1 JP 2007054597 W JP2007054597 W JP 2007054597W WO 2007100151 A1 WO2007100151 A1 WO 2007100151A1
Authority
WO
WIPO (PCT)
Prior art keywords
fraction
extract
activity
polysaccharide
precipitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/054597
Other languages
English (en)
Japanese (ja)
Inventor
Yuka Tsutsuura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAWATARI SHOUJI
TSUTSUURA KOUKICHI
Original Assignee
MAWATARI SHOUJI
TSUTSUURA KOUKICHI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAWATARI SHOUJI, TSUTSUURA KOUKICHI filed Critical MAWATARI SHOUJI
Publication of WO2007100151A1 publication Critical patent/WO2007100151A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates to an immunostimulant comprising a polysaccharide complex obtained from the mekabu strength of seaweed, and particularly to an immunostimulant (mechab sulfated galac tofucan) having the activity characteristics of leukocytes such as macrophages.
  • Wakame buds which are seaweeds, are densely populated with sporangia containing zoospores, which can be called wakame eggs, and have various functions such as giving immunity when administered to a living body. It has been made clear that
  • seaweed polysaccharides have been separated from seaweed.
  • seaweed diet has been believed to bring about health, but recently, in medical and biological research, it was reported that seaweed polysaccharides have an effect of enhancing immunity.
  • brown algae fucose-containing polysaccharides are effective in suppressing infection against human immunodeficiency virus (McClure et al., 1 991), life-prolonging effect in tumor-bearing mice (Zhuang et al., 1995), adenocarcinoma
  • McClure et al., 1 991 human immunodeficiency virus
  • adenocarcinoma An inhibitory effect on metastasis (Coombe et al., 1987) or an inhibitory effect on tumor cell growth (Ellouali et a 1., 1991) has been reported. I think that these effects include the effect of promoting leukocyte function, and in particular, examined the phagocytic leukocyte activity of seaweed polysaccharides.
  • Japanese Unexamined Patent Application Publication No. 2002-105102 is known as a technique related to an immunostimulant using such a seaweed extract.
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2002-105102
  • the ligand is a polysaccharide
  • the force S that had to be newly inferred for the chemotactic receptor on the leukocyte side, and while examining the ligands and antagonists of known chemotactic receptors, Recalling that it is an antagonist of the ratatosuka elastin 'peptide' receptor, it was possible to clarify that the elastin 'peptide' receptor itself is a receptor for the chemotactic polysaccharide. It was.
  • the present application has been made on the basis of such research, and an object thereof is to provide an immunostimulant that imparts a strong chemotactic activity to leukocytes such as macaque phages.
  • a polysaccharide extract is prepared from a mechap, and the precipitate is extracted by centrifuging the polysaccharide extract. It is characterized by this.
  • mechabu force polysaccharide extract is prepared, the polysaccharide extract is centrifuged to extract a precipitate fraction, and the precipitate fraction is anion-exchange chromatograph. It is characterized in that it is separated according to the ionic strength by the physics and a fraction having a strong anion degree is extracted from the separated liquid.
  • protein is hydrolyzed by enzymatic treatment of a solution containing the mekabu powder cake component, the hydrolyzed solution is centrifuged, and the upper part after the centrifugal separation is obtained.
  • a clear fraction is extracted to prepare a polysaccharide extract, and the polysaccharide extract is centrifuged to extract a precipitate fraction.
  • the precipitate fraction is extracted by ABCD according to the elution peak by anion exchange chromatography. It is divided into the four categories of It is characterized by the extraction of the D fraction.
  • the present invention has the following effects.
  • the immunostimulant of the present invention When the immunostimulant of the present invention is administered to a living body, the sulfated galactofucan force contained in a large amount in wakame spore (mekabu) acts on the elastin 'peptide' receptor of human phagocytic leukocytes to cause chemotaxis.
  • wakame spore mekabu
  • the fucoidan-like polysaccharides of this effort are rich in minerals such as potassium 'calcium' phosphorus' iron, vitamins such as vitamins ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ 1 ' ⁇ 2 ⁇ niacin' C, and others. Minor amounts of minerals necessary for life support and nutrients, that is, essential trace elements are included. .
  • the present invention provides a useful method for decomposing unused seaweed that can effectively use unused seaweed generated in large quantities during the period from fishing to processing of seaweed, and can reduce waste.
  • the immunostimulant having the most chemotactic activity on leukocytes is purified.
  • the seaweed used the near sea culture.
  • Human normal blood buffy coat was supplied by the Japanese Red Cross Kumamoto Blood Center.
  • Protease Actinase AS from Streptomyoes griseus was purchased from Kaken Pharmaceutical (Tokyo).
  • Endo 13 galactosidase derived from Escherichia freundH was manufactured by Seikagaku Corporation (Tokyo). Fetal bovine serum albumin was manufactured by Sigma (St. Louis, USA). Phi Cole-Park used Amersham Biosciences (Tokyo). Multiwell chambers for chemotaxis activity measurement were purchased from Neuro Probe (Bethesda, USA). For the measurement of monocytes, a polycarbonate thin film Nuclepore 'filter with a pore size of 5 IX m and for a polynuclear cell measurement of Nuclpore (Pleasant, USA) was purchased and used. As other reagents, special grades manufactured by Wako Pure Chemical Industries, Ltd.
  • the sprout spore (mekabu) portion was washed with pure water, air-dried, and finely divided by a grinder. Further, as a comparative example, chrome and mozuku, red algae paste and tokasori were air-dried and made into fine particles by a grinder.
  • the precipitated fraction was washed with 90% and pure ethanol, then lyophilized and stored at -20 ° C until use.
  • the supernatant fraction was concentrated with an evaporator, freeze-dried, and stored at 120 ° C. until use.
  • a 75% ethanol precipitate of each seaweed and a lyophilized preparation of the supernatant fraction were provided. They are weighed and then dissolved in phosphate buffered saline to be used for runaway experiments. Les
  • Mechabu's 75% ethanol precipitate fraction dry powder was dissolved with 20 mM Tris-HCl buffer (PH7.0) to 12.5 mg / ml, and 20 ml was equilibrated with the same buffer at 4 ° C. It was administered to a TOPAL DEAE-650S column ( ⁇ 2.6 cm x 36 cm, volume 190 ml). After washing the column with the same buffer, adsorbed molecules were sequentially eluted by a salt concentration gradient method up to 1.0M and fractionated every 6 ⁇ . When the sugar concentration of each fraction was measured, the elution pattern of the polysaccharide showed four peaks.
  • each fraction was pooled, and each pool was designated as ⁇ , ⁇ , C, and D fractions.
  • These four fractions were dialyzed against pure water at 4 ° C and then lyophilized. After weighing them, they were dissolved in phosphate buffered saline and used for chemotaxis activity measurement.
  • the above lyophilized D fraction was dissolved in sodium acetate buffer (pH 5.8) at a concentration of 1 mg / ml and treated with endo- ⁇ -galactosidase at a final concentration of 10 mU / ml for 60 minutes at 37 ° C. .
  • a D fraction solution containing only the solvent instead of endogalactosidase and a solution containing only 10 mU / ml endo ⁇ -galactosidase were incubated at 37 ° C for 60 minutes, respectively.
  • These samples were diluted at least 30-fold with phosphate buffered saline and used for chemotaxis experiments.
  • Trimethylsilinole (TMS) and acetylation methods were used for the degradation of polysaccharides into their derivative sugars.
  • TMS Trimethylsilinole
  • acetylation methods were used for the degradation of polysaccharides into their derivative sugars.
  • ⁇ , ⁇ -bismethylsilylacetamide was used
  • acetic anhydride was used in pyridine to form a TMS monosaccharide and a acetylated monosaccharide, respectively.
  • Quantitative analysis of the derivatized monosaccharide was performed by gas chromatography.
  • the mononuclear cell fraction was extracted from normal human buffy coat, using the dextran precipitation method and the Ficoll 'pack one concentration gradient method as described in Fernandez et al. (1978). The proportion of monocytes in this fraction was about 20% and the survival rate was over 95%.
  • the polynuclear cell fraction was donated by peripheral blood from graduate students in the field of molecular pathology and extracted according to the method of Fernandez et al. (1978). More than 95% of this fraction is neutrophil and survival rate is more than 98%. It was. These leukocyte fractions were used for chemotaxis experiments.
  • the above mononuclear cell fraction is in RPMI 1640 medium containing 10% inactivated urine fetal serum, and the polynuclear cell fraction is in Hank's medium containing 0.5% urinary serum albumin.
  • the density was adjusted to 10 6 cells / ml.
  • Chemotaxis activity was determined by using a multiwell chamber method according to the report of Falk et al. (1980), using an Ncl ore membrane having pores of 5 m (for monocytes) or 3 ⁇ m (for polynuclear cells).
  • the cell suspension was injected into the upper chamber and the sample was injected into the lower chamber, and incubated at 37 ° C for 90 minutes under 5% carbon dioxide concentration.
  • the Nucl-marked ore membrane was separated, immersed in pure ethanol to fix the cells, and then stained with Giemsa solution. The cells that migrated to the lower surface of the membrane were counted for five fields of view with a magnified light microscope.
  • a 0.1 ml sample diluted sufficiently with phosphate buffered saline was injected intradermally using a 27-gauge needle onto the back of the guinea pig that had been dehaired with Norican. After 12 hours, the animals were exsanguinated under ether anesthesia and the skin was immediately harvested and fixed with 10% formalin. After embedding the paraffin, the central part of the intradermal injection was sliced into 5 ⁇ and the specimen stained with hematoxylin eosin was observed with an optical microscope.
  • Monocyte migration activity was measured by the multi-well 'chamber method by dividing the five kinds of seaweed polysaccharide extracts into 75% ethanol-precipitated fraction and soluble fraction.
  • complement system peptide C5a having strong chemotaxis against phagocytic leukocytes and phosphate buffered saline as a sample solvent were used.
  • Figure 1 shows the results of measuring each precipitate fraction to lmg / ml. Strong migratory activity was observed for Wakame's Mekabu, and slightly weaker activity was observed for Kurome. No other brown algae, mozuku and red algae, were found to have activity. On the other hand, in the soluble fraction, no migration activity was observed in any of the forces measured for paste and chrome. Therefore, Mekabu 75% ethanol precipitation fraction was used in the subsequent experiments.
  • the main monosaccharides in the D fraction were galactose and fucose, which were contained in an approximate 1: 1 ratio. Glucose, mannose and uronic acid were absent. In addition, a large amount of sulfate groups were observed. This supports the fact that the polysaccharide of the D fraction is almost a single molecular species, and the molecule is sugaratofucan sulfate.
  • the chemotaxis activity on monocytes was measured after treating the D fraction with endo- ⁇ -galactosidase, which hydrolyzes the reducing end of intramolecular non-sulfated galactose. As shown in FIG. 6, the chemotaxis activity of the D fraction was almost completely lost. This result supports the fact that the D.sub.fraction main component, the H. galatatofucan sulfate molecule itself, is a monocyte running factor.
  • This sulfated galactofucan can be considered as a chemotactic factor for phagocytic leukocytes because it showed chemotactic activity on both monocytes and neutrophils.
  • D fraction sample obtained by treating D fraction with endo- ⁇ -galactosidase, and endo-galactosidase solution with the same final concentration was injected into the back skin of guinea pigs, and 12 hours later, the tissue sections were stained with hematoxylin-eosin and observed with a light microscope. As shown in Fig. 8, leukocyte infiltration mainly from neutrophils and monocytes was observed extensively from the dermal papillary layer to the subcutaneous fleshy membrane at the D fraction injection site.
  • monocyte elastin 'peptide' receptor Antagoest in the disaccharide ratatoses. I recalled that there was. However, since lactose has galactose as one of its component sugars (the other monosaccharide component is gnolecose), we think that elastin. It was.
  • Receptor power for sulfated galactofucan To confirm that it is an elastin 'peptide' receptor, a competition experiment was conducted using elastin 'peptide Vd-Gly-Val-Ak-Pro-Gly. The mononuclear cell fraction used for chemotaxis measurement was pretreated with various concentrations of elastin 'peptide for 60 minutes at 37 ° C, and chemotaxis activity using 75% ethanol precipitation fraction of Mekapu. When used in the measurement, chemotaxis was suppressed depending on the pre-treated elastin 'peptide concentration (Fig. 10).
  • chemotactic receptor for sulfated galactofucan is an elastin 'peptide' receptor.
  • the seaweed polysaccharide that has chemotactic activity for human phagocytic leukocytes, and 2) the chemotactic activity of the polysaccharide is inactivated by endo- ⁇ -galactosidase treatment.
  • the polysaccharide has a molecular weight of several hundred thousand, contains fucose in addition to galactose, and has a strong negative charge because it is highly sulfated. This high molecular polysaccharide can be called a component strength sulfated galactofucan.
  • the structure of the seaweed sulfate ⁇ galatatofucan has been revealed, and the only molecule that has been named G-fucoidan.
  • G-fucoidan itself is likely to be a chemotactic factor in terms of compositional monosaccharide species, degree of negative charge, molecular weight, and sensitivity to endo- ⁇ -galactosidase, but so far reports on the physiological activity of G-fucoidan There is no.
  • chemokines are linked to various chemokine receptors, complement peptide C5a, S19 ribosomal protein dimer and so on.
  • Gram-negative bacteria Skp is also a C5a receptor and formy Met- Leu-Ph e binds to formylated peptide receptor and elastin peptide binds to elastin peptide receptor to exert chemotactic activity.
  • Galactose-binding lectin is a splice variant encoded by the same gene as 3 galactosidase; it has no enzymatic activity but remains a binding site for galactose; A protein with a molecular weight of 67,000 with a tin-binding site added (Privitera, et al, 1998).
  • Elastin' peptide Receptor binds to receptor to cause monocyte chemotaxis, so this receptor is used to infiltrate monocytes into the intima during arteriosclerosis
  • Elastin' peptide Receptor binds to receptor to cause monocyte chemotaxis, so this receptor is used to infiltrate monocytes into the intima during arteriosclerosis
  • chemotactic sulfated galactofucan is a component characteristic of brown algae spores.
  • Fungi can be mentioned as microorganisms that form spores and have pathogenicity.
  • elastin 'peptide receptors may contribute to biological defense against pathogenic fungi. So far, there is no report that fungi make sulfate ⁇ galatatofucan, but I think it cannot be denied that fungi produce it. Rather Therefore, it may be necessary to actively investigate whether the fungus produces an exotic fucan sulfate or similar polysaccharide molecule.
  • the chemotactic sulfate galactofucan also induced phagocytic leukocyte infiltration by intradermal injection of guinea pigs.
  • the chemotactic factor must be able to bind to extravascular connective tissue and create a stable concentration gradient.
  • the above running factors except formyto Met- Leu-Phe and elastin 'peptide, heno. It is said that it has a phosphorus binding ability and binds to sulfated glycose 'aminoglycan in the extravascular connective tissue through the basic part responsible for it, creating a stable concentration gradient, and inducing cell invasion even in vivo.
  • FIG. 1 is a graph showing monocyte chemotaxis activity of a 75% ethanolic fraction of seaweed polysaccharide.
  • FIG. 2 is a diagram showing that the migration activity of the mekabu precipitate fraction is chemotaxis activity.
  • FIG. 3 is a diagram showing a state of separation by anion exchange chromatography.
  • FIG. 4 shows monocyte chemotaxis activity in each pool fraction of anion exchange chromatography.
  • FIG. 5 is a graph showing the concentration dependency of D fraction.
  • FIG. 6 is a graph showing the disappearance of monocyte chemotactic activity by endo ⁇ -galactosidase treatment.
  • FIG. 7 is a graph showing the neutrophil chemotaxis activity of ihigalactofucan sulfate.
  • FIG. 8 is a graph showing the ability of phagocytic leukocyte infiltration in vivo.
  • FIG. 9 is a graph showing the inhibition of monocyte chemotaxis of Hihigalactofucan sulfate by lactose.
  • FIG. 10 is a diagram showing competition inhibition by elastin 'peptide of monocyte chemotaxis reaction to sulfated galactofucan.
  • FIG. 11 Leukocyte membrane elastin ⁇ peptide ⁇ receptor elastin 'peptide and sulfate It is a coupling

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne un agent immunostimulant capable de conférer une activité chimiotactique puissante à un leucocyte tel qu'un macrophage. Le procédé d'obtention de cet agent consiste à: traiter à l'aide d'une enzyme une solution contenant un composant de 'mekabu' (sporophylle d'algue wakame (Undaria pinnatifida)) pulvérisé pour hydrolyser une protéine contenue dans la solution; centrifuger la solution pour extraire une fraction de surnageant, à partir de laquelle on prépare une solution d'extrait de polysaccharide; centrifuger la solution d'extrait de polysaccharide pour extraire une fraction de précipité; séparer ensuite la fraction de précipité en quatre fractions A, B, C et D selon les pics d'élution par chromatographie d'échange d'anions; extraire de ces fractions la fraction D, qui présente le degré anionique le plus élevé.
PCT/JP2007/054597 2006-03-03 2007-03-02 Agent immunostimulant Ceased WO2007100151A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006058363A JP3876271B1 (ja) 2006-03-03 2006-03-03 免疫賦活剤
JP2006-058363 2006-03-03

Publications (1)

Publication Number Publication Date
WO2007100151A1 true WO2007100151A1 (fr) 2007-09-07

Family

ID=37757086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/054597 Ceased WO2007100151A1 (fr) 2006-03-03 2007-03-02 Agent immunostimulant

Country Status (2)

Country Link
JP (1) JP3876271B1 (fr)
WO (1) WO2007100151A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3876271B1 (ja) * 2006-03-03 2007-01-31 馬渡 祥二 免疫賦活剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0253731A (ja) * 1988-08-15 1990-02-22 Katsumata Akira 抗癌活性物質
JP2001181303A (ja) * 1999-10-12 2001-07-03 Marui Bussan:Kk フコイダン様多糖複合体及びその製造方法並びにそれを主成分とする免疫賦活剤
JP2002265370A (ja) * 2001-03-06 2002-09-18 Suetsuna Yoko 新規なメカブ由来フコイダンおよび免疫賦活剤
JP3876271B1 (ja) * 2006-03-03 2007-01-31 馬渡 祥二 免疫賦活剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0253731A (ja) * 1988-08-15 1990-02-22 Katsumata Akira 抗癌活性物質
JP2001181303A (ja) * 1999-10-12 2001-07-03 Marui Bussan:Kk フコイダン様多糖複合体及びその製造方法並びにそれを主成分とする免疫賦活剤
JP2002265370A (ja) * 2001-03-06 2002-09-18 Suetsuna Yoko 新規なメカブ由来フコイダンおよび免疫賦活剤
JP3876271B1 (ja) * 2006-03-03 2007-01-31 馬渡 祥二 免疫賦活剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIROKO M. ET AL.: "Antitumor activity and immune response of Mekabu fucoidan extracted from Sporophyll of Undaria pinnatifida", IN VIVO, vol. 17, no. 3, 2003, pages 245 - 249, XP003017050 *
IIZUKA M.: "Mekabu Fucoidan no Kinosei", NEW FOOD IND., vol. 47, no. 9, 2005, pages 1 - 7, XP003017048 *
NAGUMO T. ET AL.: "Separation of sulfated, fucose -containing polysaccharides from the brown seaweed Sargassum kjellmanianum and their heterogeneity and antitumor activity", KITASATO ARCHIVES OF EXPERIMENTAL MEDICINE, vol. 61, no. 1, 1988, pages 59 - 67, XP003017051 *
OFUSA T.: "Kaiyo Shigen Wakame Mekabu no Fucoidan -Ko Gan.Ko Virus Sayo no Katsuyo-", FOOD RESEARCH, no. 607, 1 January 2006 (2006-01-01), pages 61 - 63, XP003017049 *

Also Published As

Publication number Publication date
JP3876271B1 (ja) 2007-01-31
JP2007230980A (ja) 2007-09-13

Similar Documents

Publication Publication Date Title
Fujiki et al. Effects of sodium alginate on the non-specific defence system of the common carp (Cyprinus carpioL.)
Wen et al. A new polysaccharide isolated from Morchella importuna fruiting bodies and its immunoregulatory mechanism
Beck et al. Invertebrate cytokines III: Invertebrate interleukin-1-like molecules stimulate phagocytosis by tunicate and echinoderm cells
Nergard et al. Structural and immunological studies of a pectin and a pectic arabinogalactan from Vernonia kotschyana Sch. Bip. ex Walp.(Asteraceae)
Inngjerdingen et al. Bioactive pectic polysaccharides from Glinus oppositifolius (L.) Aug. DC., a Malian medicinal plant, isolation and partial characterization
Park et al. The differential effect of high and low molecular weight fucoidans on the severity of collagen‐induced arthritis in mice
JP3731150B2 (ja) 軟骨型プロテオグリカンの精製方法
Kim et al. Purification and anticoagulant activity of a fucoidan from Korean Undaria pinnatifida sporophyll
Palatnik et al. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands
Bavington et al. Anti-adhesive glycoproteins in echinoderm mucus secretions
Kim et al. Noble tandem-repeat galectin of Manila clam Ruditapes philippinarum is induced upon infection with the protozoan parasite Perkinsus olseni
Fernández et al. Polysaccharides from Codium species: Chemical structure and biological activity. Their role as components of the cell wall
Shimizu et al. Activation of the alternative complement pathway by Agaricus blazei Murill
Jiang et al. Acetylation modification improves immunoregulatory effect of polysaccharide from seeds of Plantago asiatica L.
Maksimenko et al. Endothelial glycocalyx of blood circulation system. I. Detection, components, and structural organization
CN1412203A (zh) 藻类多糖的提取分离方法
WO2007100151A1 (fr) Agent immunostimulant
Sminia et al. Recognition of foreignness by blood cells of the freshwater snail Lymnaea stagnalis, with special reference to the role and structure of the cell coat
Chong et al. Nonimmune lymphocyte-macrophage interaction: II. Evidence that the interaction involves sulfated polysaccharide recognition
Saeid et al. Polysaccharides from echinoderms: unlocking health benefits and food applications–a review
KR20210104709A (ko) 식물 조직 유래 나노 섬유
Jiménez-Vega et al. 1, 3-β-D glucan binding protein (BGBP) from the white shrimp, Penaeus vannamei, is also a heparin binding protein
Li et al. Elastin peptide receptor-directed monocyte chemotactic polysaccharides derived from seaweed sporophyll and from infectious fungus
Gabius et al. Effect of microenvironment and cell-line type on carbohydrate-binding proteins of macrophage-like cells
AU2017254728B2 (en) Selectively deglycosylated vitamin D-binding protein (GcMAF), cholecalciferol (calciol), and production method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07715305

Country of ref document: EP

Kind code of ref document: A1